American Heart Journal
Volume 156, Issue 2 , Pages 201-208 , August 2008

Postmarket evaluation of breakthrough technologies

  • Sunil V. Rao, MD

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
    • Division of Cardiology, Durham Veterans Affairs Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: Sunil V. Rao, MD, Durham VA Medical Center, 508 Fulton Street (111A) Durham, NC 27705.
    • ,
  • Robert M. Califf, MD

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
    • Duke Translational Medicine Institute, Durham, NC
    • Duke Center for Education and Research on Therapeutics, Durham, NC
    • ,
  • Judith M. Kramer, MD, MS

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
    • Duke Center for Education and Research on Therapeutics, Durham, NC
    • ,
  • Eric D. Peterson, MD, MPH

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
    • Duke Center for Education and Research on Therapeutics, Durham, NC
    • ,
  • Thomas P. Gross, MD, MPH

      Affiliations

    • Center for Devices and Radiological Health, United States Food and Drug Administration, Rockville, MD
    • ,
  • Carl J. Pepine, MD

      Affiliations

    • Division of Cardiovascular Medicine, University of Florida, Gainesville, FL
    • ,
  • David O. Williams, MD

      Affiliations

    • Division of Cardiology, Rhode Island Hospital, Providence, RI
    • ,
  • Dennis Donohoe, MD

      Affiliations

    • Cordis Corporation, Warren, NJ
    • ,
  • Ron Waksman, MD

      Affiliations

    • Division of Cardiology, Washington Hospital Center, Washington, DC
    • ,
  • Roxana Mehran, MD

      Affiliations

    • Cardiovascular Research Foundation, Columbia University Medical Center, New York, NY
    • ,
  • Mitchell W. Krucoff, MD

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC

Received 24 January 2008 ,Accepted 24 January 2008.

References 

  1. American Heart Association Web page . AHA statistical update. Heart disease and stroke statistics: 2006 update. Available at http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.105.171600v1Last accessed July 19, 2006
  2. Foot DK, Lewis RP, Pearson TA, et al. Demographics and cardiology, 1950-2050. J Am Coll Cardiol. 2000;35:1067–1081
  3. U.S. Food and Drug Administration Web site . Guidance for industry and FDA staff: expedited review of premarket submissions for devices. Available at http://www.fda.gov/CDRH/mdufma/guidance/108.htmlLast accessed April 20, 2006
  4. Groeneveld PW, Heidenreich PA, Garber AM. Trends in implantable cardioverter-defibrillator racial disparity: the importance of geography. J Am Coll Cardiol. 2005;45:72–78
  5. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004;110:508–514
  6. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130
  7. Myerburg RJ, Feigal DW, Lindsay BD. Life-threatening malfunction of implantable cardiac devices. N Engl J Med. 2006;354:2309–2311
  8. O'Shea JC, Kramer JM, Califf RM, et al. Part I: Identifying holes in the safety net. Am Heart J. 2004;147:977–984
  9. Peterson ED, Hirshfeld JW, Ferguson TB, et al. Part II: Sealing holes in the safety net. Am Heart J. 2004;147:985–990
  10. Kessler DA. Introducing MEDWatch: a new approach to reporting medications and device adverse effects and product problems. JAMA. 1993;269:2765–2768
  11. Gardner S, Flack M. Designing a medical device surveillance network: report to congress.. Centers for Devices and Radiological Health Web page. Food and Drug Administration Web site. Available at http://www.fda.gov/cdrh/postsurv/medsun.html1999;Updated October 15, 1999. Last accessed April 20, 2006
  12. U.S. Food and Drug Administration . Food and Drugs, Food and Drug Administration, Department of Health and Human Services, Medical Devices, Pre-market approval of medical devices (Title 21, Vol. 8). Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=814&showFR=12007;Last accessed June 24, 2008
  13. Center for Devices and Radiological Health . Ensuring the safety of marketed medical devices: CDRH's Medical Device Postmarket Safety Program. Page 31, 2006. Available at www.fda.gov/cdrh/postmarket/mdpi-report.pdf2006;Last accessed January 22, 2007
  14. Brown SL, Bezabeh S, Duggirala HJ. Center for Devices and Radiological Health Condition of Approval Studies as a Postmarket tool for PMA approved cohorts 1998-2000. Available at www.fda.gov/oc/whitepapers/epi_rep.pdfLast accessed January 22, 2007
  15. Institute of Medicine . Committee on Postmarket Surveillance of Pediatric Medical Devices.. In:  Field M,  Tilson H editor. Safe medical devices for children. Washington, DC: National Academies Press; 2006;p. 183–198
  16. Kaplan AV, Baim DS, Smith JJ, et al. Medical device development: from prototype to regulatory approval. Circulation. 2004;109:3068–3072
  17. Manufacturer and User Facility Device Experience Database MAUDE) . Center for Devices and Radiological Health resources Web page. Food and Drug Administration Web site. Available at http://www.fda.gov/cdrh/maude.htmlLast accessed January 20, 2006
  18. Holmes DR, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634–640
  19. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942–1947
  20. Rao SV, Shaw RE, Brindis RG, et al. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol. 2006;97:1478–1481
  21. Muni N, Gross TP. Problems with drug-eluting coronary stents—the FDA perspective. N Engl J Med. 2004;351:1593–1595
  22. Wood S. Boston Scientific recalls additional 85 000 TAXUS stents; Brigham and Women's yanks Taxus from cath labs. Heartwire, 2004. Available at http://www.theheart.org/article/149651.do2004;Last accessed April 20, 2006
  23. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991;324:13–17
  24. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–1671
  25. Virmani R, Kolodgie FD, Farb A. Drug-eluting stents: are they really safe?. Am Heart Hosp J. 2004;2:85–88
  26. Donohoe D. Cordis Corporation alert letter: CYPHER stent. MedWatch Safety Alert Web page. Food and Drug Administration Web site. Available at http://www.fda.gov/bbs/topics/news/cordis_ltr.pdfLast accessed January 22, 2007
  27. FDA updates information for physicians on Cordis Cypher Stent. FDA talk paper.. Food and Drug Administration Web site, 2003. Available at http://www.fda.gov/bbs/cdrh/safety/cypher.html2003;Last accessed April 20, 2006
  28. Alonge L, Kroen M. FDA Public Health Web Notification: final update of information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis CYPHER sirolimus-eluting coronary stent. Food and Drug Administration Web site. Available at http://www.fda.gov/cdrh/safety/cypher3.htmlLast accessed February 24, 2006
  29. O'Riordan M. Boston Scientific is recalling approximately 200 TAXUS paclitaxel-eluting coronary stents. Heartwire, 2004. Available at http://www.theheart.org/article/148291.do2004;Last accessed April 20, 2006
  30. Nainggolan L. Row over temporary suspension of Taxus stent. Heartwire, 2005. Available at http://www.theheart.org/article/598705.do2005;Last accessed April 20, 2006
  31. Wood S. Taxus “no deflate” problems continue says Wall Street Journal, but FDA unconcerned. Heartwire, 2005. Available at http://www.theheart.org/article/523237.do2005;Last accessed July 19, 2006
  32. Meier B. FDA plans to intensify oversight of heart devices. N Y Times. 2006;Available at http://www.nytimes.com/2006/04/07/business/07device.html?ex=1302062400&en=8585ea9669704e68&ei=5088&partner=rsssnyt&emc=rssLast accessed May 29, 2008
  33. Wood S. The Guidant recall: device strengths and weaknesses in the spotlight, 2005. Available at http://www.theheart.org/article/512423.do2005;Last accessed April 20, 2006
  34. U.S. Department of Health and Human Services . The least burdensome provisions of the FDA Modernization Act of 1997: concept and principles; final guidance for FDA and industry.. Center for Devices and Radiological Health resources Web page. Food and Drug Administration Web site. Available at http://www.fda.gov/cdrh/ode/guidance/1332.pdfLast accessed January 22, 2007
  35. Kereiakes DJ, Kuntz RE, Mauri L, et al. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol. 2005;45:1206–1212
  36. Hodgson JM, King SB, Feldman T, et al. SCAI statement on drug-eluting stents: practice and healthcare delivery implications. Cathet Cardiovasc Int. 2003;58:397–399

 The opinions or assertions presented herein are the private views of the authors and are not to be construed as conveying either an official endorsement or criticism by the US Department of Health and Human Services, the Public Health Service, or the Food and Drug Administration.

 Funding for this manuscript was provided by the Duke Clinical Research Institute (DCRI). Additional funding for the DCRI/American College of Cardiology “think tank” meeting was provided by the following sponsors: Medtronic, Inc, Abbott Vascular Devices, Cordis Corporation, and Guidant Corporation.

 Sunil V. Rao, MD, has no relationships to disclose. Robert M. Califf, MD is the director of the Duke Translational Medicine Institute and the former director of the Duke Clinical Research Institute, which has relationships with Medtronic, Guidant, Cordis/Johnson & Johnson, and St Jude Medical; all funding is administered through Duke University programs. Judith M. Kramer, MD, has no relationships to disclose. Eric D. Peterson, MD, MPH, has no relationships to disclose. Thomas P. Gross, MD, MPH, has no relationships to disclose. Carl J. Pepine, MD, has no relationships to disclose. David O. Williams, MD, is a consultant for Cordis Corporation, a consultant for Guidant Corporation, and chairs a data safety monitoring board for Abbott Vascular. Dennis Donohoe, MD, is an employee of Cordis Corporation. Ron Waksman, MD, is a consultant for and receives grant support from Medtronic and Boston Scientific Corporation. Roxana Mehran, MD, receives speaker's bureaus from Boston Scientific Corporation, Cordis Corporation, and The Medicines Company, and receives research grants from Boston Scientific Corporation, Cordis Corporation, The Medicines Company, and Conor Medsystems. Mitchell W. Krucoff, MD, has research/scientific consulting relationships with Cordis Corporation/Johnson & Johnson, Boston Scientific Corporation, Medtronic, Abbott (Guidant), Conor Medsystems, Terumo, Biotronik, and St Jude.

PII: S0002-8703(08)00321-9

doi: 10.1016/j.ahj.2008.01.036

American Heart Journal
Volume 156, Issue 2 , Pages 201-208 , August 2008

Article Tools